NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1 / CDK1 Pathway and Is a Potential Prognostic Biomarker
Cancer Science · 2025
DOI: 10.1111/cas.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Wendi Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Cyclin B1, CDC2 Protein Kinase, Adenocarcinoma of Lung, NFATC Transcription Factors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Natural Science Foundation of Chongqing, Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University, the Project of Chongqing Technology Innovation and Appli-cation Development.
Abstract (Originalsprache)
Nuclear factor of activated T‐cells, cytoplasmic 4 (NFATc4), a transcription factor of the NFAT family, has been reported to participate in the tumorigenesis and progression of several cancers. However, the function and regulation of NFATc4 in lung adenocarcinoma (LUAD) remain poorly understood. Here, we report for the first time that NFATc4 is significantly overexpressed in LUAD tissues, and high NFATc4 expression correlates with lymphatic metastasis, advanced tumor stage, and poor prognosis in patients. Subsequent functional studies revealed that NFATc4 depletion inhibits LUAD cell viability, proliferation, and tumor growth by inducing cell cycle arrest in the G2/M phase and apoptosis. A mechanistic study shows that NFATc4 knockdown leads to significant enrichment of cellular process‐related pathways and differentially expressed genes, especially downregulated genes Cyclin B1 (CCNB1) and cyclin‐dependent kinase 1 (CDK1). NFATc4 directly binds to the CCNB1 promoter to regulate the CCNB1/CDK1 pathway, resulting in cell cycle arrest and inhibition of cell proliferation. This study identifies NFATc4/CCNB1/CDK1 as a novel regulatory pathway involved in LUAD development and provides a potential prognostic biomarker and molecular therapeutic target for LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
ORCID-Profile: Zhenzhou Yang, Xiaoyue Zhang
Förderung
- the Natural Science Foundation of Chongqing
- Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University
- the Project of Chongqing Technology Innovation and Appli-cation Development
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Yang, W., Wu, X., Cai, F., Guo, Z., Xu, Z., Peng, Y., Yang, Z., & Zhang, X. (2025). NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1 / CDK1 Pathway and Is a Potential Prognostic Biomarker. Cancer Science. https://doi.org/10.1111/cas.70122
Vancouver
Yang W, Wu X, Cai F, Guo Z, Xu Z, Peng Y, et al. NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1 / CDK1 Pathway and Is a Potential Prognostic Biomarker. Cancer Science. 2025. doi:10.1111/cas.70122
BibTeX
@article{Yang2025,
author = {Yang, Wendi and Wu, Xue and Cai, Fanghao and Guo, Zhengjun and Xu, Zaicheng and Peng, Yuan and Yang, Zhenzhou and Zhang, Xiaoyue},
title = {NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1 / CDK1 Pathway and Is a Potential Prognostic Biomarker},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70122}
}
EUVIMED